MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Category: DRUG TRIAL

Proportion
Tiash SahaJuly 19, 2018

Roche’s New Drug Shows Better Results than Renowned Tamiflu in Flu Patients

Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.

Proportion
Tiash SahaJune 3, 2018

This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’

AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.

Proportion
Tiash SahaMay 28, 2018

15 Promising New Cancer Drugs in Late-Stage Clinical Development (2018)

Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018. The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.

Proportion
Tiash SahaApril 5, 2018

Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review

The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...

Proportion
Tiash SahaMarch 31, 2018

New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status

Chinese biotech, Maxinovel Pharma’s immuno-oncology drug candidate- MAX-40279 received Orphan Drug designation from the US FDA for the treatment of ...

Proportion
Tiash SahaMarch 27, 2018

Ovarian Cancer Drug Zejula Shows Historical Results in Combination for Hard-to-Treat Cancer

KEY POINTS Zejula plus Keytruda improved the clinical benefits significantly in difficult-to-treat ovarian cancer patients than any one of them ...

Proportion
Tiash SahaFebruary 23, 2018

Merck’s New Class of Drugs Shows Potential against Resistant Cancers

KEY POINTS ERK inhibitors are the new class of drugs in development for resistant cancers Merck’s ERK inhibitor, MK-8353 in ...

Proportion
Tiash SahaFebruary 20, 2018

8 Most Promising Vaccines Under Development (2018)

KEY POINTS Here are some of the most promising vaccines on their way in 2018. Vaccines protect against a large ...

Proportion
Tiash SahaFebruary 12, 2018

Pfizer’s Lorlatinib Gets FDA Priority Review Status to Treat ALK-Positive Lung Cancer

KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor.  Last year, lorlatinib had received Breakthrough Therapy designation from the ...

Proportion
Tiash SahaFebruary 8, 2018

Lupin & Yoshindo’s First Enbrel Biosimilar Targets Regulatory Approval

KEY POINTS YL Biologics announced the successful clinical outcome of YLB113- biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® ...

  • 1
  • 2
Privacy Policy Terms Payment Policy Education Contact Us About us